Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis

Inclusion Criteria: * Age: 18 to 75years old, male or female; * ECOG PS: 0-2 points; * Patients with pancreatic ductal adenocarcinoma diagnosed by histology or cytology; * Expected survival time\> 3 months; * The functions of important organs meet the following requirements; * The maximum diameter of single lesion ≤ 5cm or the number of multiple lesions ≤ 5 and the maximum diameter ≤ 3cm; * Measurable lesions that meet RECIST criteria. 1. Platelet ≥75×109/L, hemoglobin ≥85g/L，white blood cell ≥ 3.0 × 109 / L; 2. Total bilirubin ≤ 1.5 times upper limit of normal value (ULN) ; ALT and AST ≤ 5 times ULN ; 3. Albumin ≥ 28g / L; 4. Creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 50ml / min; * Women of childbearing age must undergo a negative pregnancy test (βHCG) before starting treatment. Women and men of childbearing age (sexual relationships with women of childbearing age) must agree to use them effectively during treatment and 3 months after the last dose of treatment Contraceptive measures; * Signature of patient information and informed consent. * Patients who did not participate in other clinical trials within 4 weeks before screening; those who failed in other trials but met the requirements of this trial could be enrolled. Exclusion Criteria: * Patients with distant metastasis include but not limited to lung metastasis, bone metastasis and brain metastasis; * Other serious diseases or conditions, including congestive heart failure (NYHA grade III or IV), unstable angina, myocardial infarction and cerebral infarction in the past 6 months, severe arrhythmia, prolonged QT interval, active HIV infection or HIV disease, mental disorders, drug abuse, etc; * Women who are pregnant or nursing, or have fertility but refuse to take contraceptive measures; * During the enrollment period, a serious active infection requiring antibiotic intravenous treatment occurred; * In addition to cervical carcinoma in situ, basal cell carcinoma and superficial bladder tumor (TA, tis \& T1). Any cancer cured for more than 3 years before enrollment was allowed to be enrolled; * Patients who cannot follow the trial protocol or cannot cooperate with follow-up;